When diagnosed with glioblastoma, a deadly form of brain cancer that killed U.S. Sen. Ted Kennedy (D-MA) in 2009, doctors and patients have limited options to cope with the tumor. Are widely distributed in brain tissue and are often too numerous to remove surgically or attack effectively with chemotherapy and radiation. Scientists now report that they've developed a diverse drug showed great promise in homing in on and destroy the deadly brain tumors in mice.
Drugs is a Swiss army knife against glioblastoma type, with three separate parts all linked together. He has received peptide - or short protein - that bhulláin the drug to the tumor and specifically binds to cancer cell surfaces, another peptide that triggers cell death by attacking the power centers of cells, and nanoparticle that acts as both imaging agents to watch the tumors with MRI and a cancer killer. When given to one group of mice with glioblastomas, treated mice lived longer than untreated ones. And in the second group of mice with brain tumors, the drug cured 9 of 10 mice and extended the survival of other mice, according to a release.
Of course, curing cancer in mice often do not translate into a breakthrough in treating the person. But he said behind the project scientists, led Sanford-Burnham Institute for Medical Research (Sanford-Burnham) and the Salk Institute for Biological Studies, achieved some important features of the new drugs that could make the medicine is effective and non- toxic to brain cancer.
The prognosis for people diagnosed with glioblastoma and poor patients often die more often in less than a year, which means there is plenty of room to prolong the survival of patients with new therapies. Kennedy battle with cancer lasted for less than two years.
"This is nanosystem unique for two reasons. First, by linking the cell-killing peptide nanacháithníní made it possible for us to deliver it specifically to tumors, virtually eliminate killer peptide toxicity to normal tissues . Second, researchers and clinicians are generally satisfied if they are not able to deliver more drugs to tumor or normal tissues. we concluded only that, but they were able to design our delivery nanacháithníní the right killer peptide when It acts-the mitochondria, the energy-generating cell center, "Dr. Erkki Ruoslahti, senior author of the study and a professor in both NCI-designated Sanford-Burnham Center for Cancer in La Jolla and the Center for Nanomedicine, said in statement.
Drugs is a Swiss army knife against glioblastoma type, with three separate parts all linked together. He has received peptide - or short protein - that bhulláin the drug to the tumor and specifically binds to cancer cell surfaces, another peptide that triggers cell death by attacking the power centers of cells, and nanoparticle that acts as both imaging agents to watch the tumors with MRI and a cancer killer. When given to one group of mice with glioblastomas, treated mice lived longer than untreated ones. And in the second group of mice with brain tumors, the drug cured 9 of 10 mice and extended the survival of other mice, according to a release.
Of course, curing cancer in mice often do not translate into a breakthrough in treating the person. But he said behind the project scientists, led Sanford-Burnham Institute for Medical Research (Sanford-Burnham) and the Salk Institute for Biological Studies, achieved some important features of the new drugs that could make the medicine is effective and non- toxic to brain cancer.
The prognosis for people diagnosed with glioblastoma and poor patients often die more often in less than a year, which means there is plenty of room to prolong the survival of patients with new therapies. Kennedy battle with cancer lasted for less than two years.
"This is nanosystem unique for two reasons. First, by linking the cell-killing peptide nanacháithníní made it possible for us to deliver it specifically to tumors, virtually eliminate killer peptide toxicity to normal tissues . Second, researchers and clinicians are generally satisfied if they are not able to deliver more drugs to tumor or normal tissues. we concluded only that, but they were able to design our delivery nanacháithníní the right killer peptide when It acts-the mitochondria, the energy-generating cell center, "Dr. Erkki Ruoslahti, senior author of the study and a professor in both NCI-designated Sanford-Burnham Center for Cancer in La Jolla and the Center for Nanomedicine, said in statement.
0 comments:
Post a Comment